{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-24-015838","form_type":"8-K","ticker":"ACRS","cik":"0001557746","company_name":"Aclaris Therapeutics, Inc.","filed_at":"2024-11-18T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.779697+00:00","generated_at":"2026-05-29T23:01:50.630762+00:00","sec_items":["1.01","3.02","5.02","7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Aclaris licenses anti-TSLP/IL4R biologics, raises $80M, appoints Davis as President/COO","bullets":["License deal: $30M upfront, $4.5M dev reimbursement, warrants for 14.3M shares at $0.00001, up to $920M milestones, royalties.","Private placement: 35.6M shares at $2.25 for $80M gross; closed Nov 19; led by Vivo Capital; cash runway into 2028.","Leadership additions: Hugh Davis as President/COO + Class III director; Steven Knapp EVP Regulatory & Quality.","Adopted 2024 Inducement Plan reserving 2M shares; Davis granted options for 375K shares, RSU for 107K shares."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-24-015838","json":"https://secwatch.observer/filing/0001558370-24-015838.json","markdown":"https://secwatch.observer/filing/0001558370-24-015838.md","text":"https://secwatch.observer/filing/0001558370-24-015838.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1557746/000155837024015838/0001558370-24-015838-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1557746/000155837024015838/acrs-20241116x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-29T23:01:50.630762+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"3ee71f1906","claim":"Hugh Davis was appointed as Class III Director at Aclaris Therapeutics, Inc..","evidence_excerpt":"The Board also appointed Dr. Davis to the Board, effective November 18, 2024, to serve as a Class III director","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1557746/000155837024015838/0001558370-24-015838-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Class III Director"}],"fact_type":"executive_change"},{"claim_id":"b9d36fefb3","claim":"Neal Walker changed role as President at Aclaris Therapeutics, Inc..","evidence_excerpt":"In connection with Dr. Davis’s appointment, Neal Walker will no longer serve as the Company’s President but will continue to serve as the Company’s Interim Chief Executive Officer.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1557746/000155837024015838/0001558370-24-015838-index.htm","confidence":0.9,"family_label":"Executive change","details":[{"label":"Action","value":"will no longer serve role"},{"label":"Role","value":"President"}],"fact_type":"executive_change"},{"claim_id":"ebb34a570d","claim":"Hugh Davis was appointed as President and Chief Operating Officer at Aclaris Therapeutics, Inc..","evidence_excerpt":"On November 16, 2024, the board of directors (the “ Board ”) of the Company appointed Hugh Davis, Ph.D., as the Company’s President and Chief Operating Officer effective November 18, 2024.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1557746/000155837024015838/0001558370-24-015838-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"President and Chief Operating Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}